BIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Results of Operations and Financial Condition

BIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02

Results of Operations and Financial Condition.

On May 11, 2017, we issued a press release announcing our
financial results for the three months ended March 31, 2017. A
copy of the press release and accompanying information is
attached as Exhibit 99.1 to this current report.

The information in this Item 2.02, and Exhibit 99.1 attached
hereto, is being furnished and shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section.
The information in this current report shall not be incorporated
by reference into any registration statement or other document
filed with the Securities and Exchange Commission, whether filed
before or after the date hereof regardless of any general
incorporation language in any such filing, unless we expressly
set forth in such filing that such information is to be
considered filed or incorporated by reference therein.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

99.1Press Release dated May 11, 2017


About BIOCEPT, INC. (NASDAQ:BIOC)

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

BIOCEPT, INC. (NASDAQ:BIOC) Recent Trading Information

BIOCEPT, INC. (NASDAQ:BIOC) closed its last trading session 00.00 at 1.84 with 975,034 shares trading hands.

An ad to help with our costs